ImmuPharma plc (AIM:IMM)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 22.46M -16.0% |
| Revenue (ttm) | n/a |
| Net Income | -1.81M |
| EPS | -0.00 |
| Shares Out | 623.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,904,035 |
| Open | 3.405 |
| Previous Close | 3.460 |
| Day's Range | 3.302 - 3.900 |
| 52-Week Range | 3.300 - 19.400 |
| Beta | 3.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 25, 2026 |
About ImmuPharma
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology; and CDx, a companion diagnostic, which is in cl... [Read more]
Financial Performance
Financial StatementsNews
AIM Market Roundup: Sunda Energy, Gfinity, Tracsis
Sunda Energy, Gfinity, Tracsis, Immupharma and Premier African are today's biggest movers on London's AIM market
ImmuPharma Annual report: H2 2025
ImmuPharma has published its H2 2025 annual report on May 27, 2026.
ImmuPharma Annual report: H2 2025
ImmuPharma has published its H2 2025 annual report on May 27, 2026.
ImmuPharma Transcript: Investor update
P140 remains the core focus, with licensing deals anticipated this year and strong scientific support. New funding, driven by shareholder interest, enables accelerated development of Kapiglucagon for Type I diabetes, targeting a $3 billion market with a rapid 18–24 month timeline.
ImmuPharma Press release: Investor update
ImmuPharma issued a press release on March 20, 2026, disclosing material business information to investors.
ImmuPharma Slides: Investor update
ImmuPharma has posted slides in relation to its latest quarterly earnings report, which was published on March 20, 2026.
AIM Market Roundup: Tern, T42 IoT, Atlantic Lithium
Tern, T42 IOT, Atlantic Lithium are today's top risers, while Wishbone, ImmuPharma take the biggest fall on London's AIM market
AIM Market Roundup: Immupharma, Pebble Beach, Tungsten West
Immupharma, Pebble Beach, Tungsten West, SkinBioTherapeutics and PHSC are today's biggest risers and fallers on London's AIM market
FTSE Flat as Wall Street Gains Fail to Inspire
FTSE mostly flat as housebuilders outperform; ImmuPharma slides, US gains fail to lift London sentiment. The post FTSE Flat as Wall Street Gains Fail to Inspire appeared first on Investomania .
AIM Market Roundup: Trellus Health, Great Western Mining, EMV Capital
Trellus Health, Great Western Mining, EMV Capital are today's top risers, while EQTEC, ImmuPharma take the biggest fall on London's AIM
AIM Market Roundup: ImmuPharma, Rockfire Resources, Likewise
ImmuPharma, Rockfire Resources, Likewise are today's top risers, while Trellus Health, Mercantile Ports take the biggest fall on London's AIM
AIM Market Roundup: Dewhurst, Metir, Tertiary Minerals
Dewhurst, Metir, Tertiary Minerals are today's top risers, while LifeSafe, ImmuPharma take the biggest fall on London's AIM market
AIM Market Roundup: ImmuPharma, N4 Pharma, Versarien
Immupharma, N4 Pharma, Versarien are today's top risers, while Wishbone, Empyrean take the biggest fall on London's AIM market
AIM Market Roundup: Catenai, Europa Oil & Gas, Faron Pharma
Catenai, Europa Oil & Gas, Faron Pharma are today's top risers, while Simec Atlantis, Immupharma take the biggest fall on London's AIM market
FTSE Rises as Investors Eye Tariff Deadline
FTSE rises as tariff deadline looms, Hiscox and Faron climb on results, ImmuPharma sinks on losses. The post FTSE Rises as Investors Eye Tariff Deadline appeared first on Investomania .
ImmuPharma Quarterly report: H1 2025
ImmuPharma has published its H1 2025 quarterly earnings report on August 6, 2025.
ImmuPharma Annual report: H2 2024
ImmuPharma has published its H2 2024 annual report on May 19, 2025.
ImmuPharma Annual report: H2 2024
ImmuPharma has published its H2 2024 annual report on May 19, 2025.
FX positioning info - Net speculative EUR longs surged in a sharp rise from previous week
This is a snapshot of speculative positioning in major currencies from traders in the futures market, reported weekly by the CFTC through the IMM (International Monetary Market). EUR: Net speculative ...
Data show speculative traders have flipped from a net short to a net long position on euro
The IMM CFTC positioning data, released weekly by the Commodity Futures Trading Commission (CFTC), provides insights into how speculative traders, such as hedge funds and large investors, are position...
AIM Market Roundup: Immupharma, Poolbeg, Xeros
ImmuPharma, Poolbeg Pharma, Xeros Technology, RBG Holdings, Coro Energy are today's biggest risers and fallers on London's AIM market
Three Quick Facts: Norman Broadbent, Computacenter, Immupharma
Norman Broadbent, Computacenter, ImmuPharma are Tony Cross's three picks from today's financial market news